Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy. - Wikidata - wikimedia - TriplyDB

Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy.

Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy.

http://www.wikidata.org/entity/Q34445911

about

Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus Coinfection with Hepatitis C Virus and Human Immunodeficiency Virus: Virological, Immunological, and Clinical Outcomes Viral hepatitis in HIV infection.HCV and HIV co-infection: mechanisms and management.Evaluation of Lassa antiviral compound ST-193 in a guinea pig model.Update on Hepatitis C Virus and HIV Coinfection.The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive Individuals.Treating viral hepatitis C: efficacy, side effects, and complications.What the infectious disease physician needs to know about pegylated interferon and ribavirin.Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients.Pegylated interferon 2a and 2b in combination with ribavirin for the treatment of chronic hepatitis C in HIV infected patients.HIV/HCV-coinfection: which role can new antiretrovirals such as integrase inhibitors play?The treatment of chronic hepatitis C virus infection in HIV co-infection.Pharmacological significance of triazole scaffold.Clinical syndromes and consequences of antiretroviral-related hepatotoxicity.HIV-HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians.Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus co-infected patients (ANRS CO13-HEPAVIH).Inhibition of HCV by the serpin antithrombin III Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients.Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment.Severe weight loss in HIV / HCV-coinfected patients treated with interferon plus ribavirin: incidence and risk factors.

P2860

Q24240929-DA7D2881-9A33-4118-BD16-67BBA1488F23 Q27488883-E5A55DA8-B23E-4704-983E-7999A9AAC4A8 Q34086980-CF57D429-7DC7-4D0E-BB60-AFF55858A376 Q35090634-87A19C78-9796-487C-8CE1-794E7886B4AD Q35870592-10462991-6F42-4CEA-9A26-901D238F6A9B Q35906047-8188AE5F-350D-4B3E-A202-869DC2242335 Q35960026-9E66762E-A2D1-4A16-B641-90DBF3C9C4C3 Q36564615-5F54F437-CCFD-4C4F-BF4E-C4ECEDEEE187 Q36811232-425BD971-6A4D-454F-8B40-00D27F6B18F5 Q37111444-03B13781-F191-45DD-8D72-55A5C4D60DC4 Q37390380-024DEAE4-8F08-4C3D-90E5-F460B5DC46E8 Q37644125-03CCD565-05E5-4079-9F00-585050ADA1EB Q37691055-36CE3DAB-E699-4E35-9FAF-7B07A8E14147 Q37768161-3E9E7EAD-6203-433C-A7F7-65F9AAEB0733 Q37784777-A6E762C6-9B09-4510-A721-1732B64E41C6 Q38003205-77F0E4A9-3B4A-4628-9C11-1B1A155D1F57 Q41923080-9171FEE2-8BA6-4EF1-9A0D-D66EFE1A9A43 Q42406960-A2B5E260-39C0-42ED-85F0-7A3378D4D0A3 Q44189369-DA78D399-756A-4C3B-AFA1-EA17D14BD817 Q45422517-7DAAF272-3E3C-4DB4-84ED-2152F84E7E02 Q47244577-74C971C9-28E9-42B7-ADAB-E0DEA22870C8

P2860

Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy.

http://www.wikidata.org/entity/Q34445911

description

2005 nî lūn-bûn

@nan

2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Risk factors for symptomatic m ...... plus ribavirin-based therapy.

@ast

Risk factors for symptomatic m ...... plus ribavirin-based therapy.

@en

Risk factors for symptomatic m ...... plus ribavirin-based therapy.

@nl

type

label

Risk factors for symptomatic m ...... plus ribavirin-based therapy.

@ast

Risk factors for symptomatic m ...... plus ribavirin-based therapy.

@en

Risk factors for symptomatic m ...... plus ribavirin-based therapy.

@nl

prefLabel

Risk factors for symptomatic m ...... plus ribavirin-based therapy.

@ast

Risk factors for symptomatic m ...... plus ribavirin-based therapy.

@en

Risk factors for symptomatic m ...... plus ribavirin-based therapy.

@nl

P1433

Q34445911-CF1615ED-D6E0-452D-AD0C-7F243624742A

P1476

Q34445911-6E88FD1B-AF72-480F-BFEC-84D41F8E8E07

P2093

Q34445911-00835A6C-D701-46EF-947A-3E96927C6028

Q34445911-329CED51-BF16-4FF0-B9BC-A90502E5152E

Q34445911-33FB8287-1866-462E-8361-E105B7DE1239

Q34445911-37C27AF1-BAFB-43C4-947E-18ADB57D9245

Q34445911-68725CA9-5765-47BE-B9C7-C649242D9C6C

Q34445911-732DED61-E3D0-4D46-A5EB-F30669A27FBE

Q34445911-A0B1564F-FF34-4CFA-A777-E918B55BB836

Q34445911-CE901C98-7F03-4DF8-8E96-720CFFA09680

Q34445911-D6074B6A-B8CE-4F0E-80E8-DD62A69696C6

Q34445911-E3FE8612-33CE-4BF3-B599-3A4C502F1EE2

P304

Q34445911-0B4F4838-3AA4-49BB-97FD-D84B0F16C6F0

P31

Q34445911-95D05B26-DD0F-4AB2-9CBE-1FA34F0C0C2D

P356

Q34445911-A98013DF-883B-4265-8A7D-CA6A4DE31429

P407

Q34445911-9C8FA1A5-C290-470A-8588-1C1FAD39C31A

P433

Q34445911-A4EFEEC4-1C13-4E35-B4EA-A77358B450C4

P478

Q34445911-8EA9254D-D665-42AD-B840-84D7668E03E3

P50

Q34445911-07654C5A-4876-448E-BDCB-6C30F4A352CD

Q34445911-81F2DC4C-123B-4F32-B75D-465AA9A17BF4

Q34445911-DE749030-B053-4B33-ABCF-04050C98AAA9

Q34445911-E86394A3-C9A0-4D46-BEE3-2EC40992250F

P577

Q34445911-9EB3F502-AA8B-45AD-B812-D70B9536A934

P698

Q34445911-29CF341D-3377-44D6-9C16-E4A6F2BC1E1D

P356

01.QAI.0000174649.51084.46

P1433

Journal of Acquired Immune Deficiency Syndromes

P1476

Risk factors for symptomatic m ...... plus ribavirin-based therapy.

@en

P2093

ANRS Hc02-Ribavic Study Team

http://www.w3.org/2001/XMLSchema#string

Christian Perronne

http://www.w3.org/2001/XMLSchema#string

Cécile Goujard

http://www.w3.org/2001/XMLSchema#string

Dominique Salmon-Ceron

http://www.w3.org/2001/XMLSchema#string

Eric Rosenthal

http://www.w3.org/2001/XMLSchema#string

Firouzé Bani-Sadr

http://www.w3.org/2001/XMLSchema#string

Françoise Lunel-Fabiani

http://www.w3.org/2001/XMLSchema#string

Gilles Pialoux

http://www.w3.org/2001/XMLSchema#string

Lionel Piroth

http://www.w3.org/2001/XMLSchema#string

Michèle Bentata

http://www.w3.org/2001/XMLSchema#string

P304

47-52

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/01.QAI.0000174649.51084.46

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P50

Françoise Lunel-Fabiani

P577

2005-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16123681

http://www.w3.org/2001/XMLSchema#string